The most prominent terminological problems in reproductive medicine
E. N. Andreeva,
G. A. Melnichenko,
O. R. Grigoryan,
R. V. Rozhivanov,
R. K. Mikheev,
M. O. Chernova,
E. R. Rozhivanova https://doi.org/10.14341/brh12737
Abstract
Constant improvement of professional skills and competence are essential components of modern post diploma medical education in the 21st century. Despite of world-wide spread of evidence-based medicine many physicians from such areas as obstetrics, gynecology, andrology, endocrinology, cardiology. gerontology etc. still use outdated and incorrect terminology from reproductive medicine. The such unfavourable trend leads to serious increasement of insufficient/overdiagnosis, treatment mistakes and poor outcomes such as sexual dysfunction, infertility and comorbidity. The present article presents actual interpretations and characterization of gynecological and andrological terms such us menopausal hormonal therapy (MHT) and hormone replacement therapy (HRT) among females and male hypogonadism.
About the Authors
E. N. Andreeva
Endocrinology Research Centre of the Ministry of Health of Russian Federation; Russian University of Medicine of Ministry of Health of Russian Federation
Russian Federation
Competing Interests:
Russian Federation
Elena N. Andreeva, MD, Doctor of Sciences, professor
Moscow
Competing Interests:
Авторы декларируют отсутствие явных и потенциальных конфликтов интересов, связанных с содержанием настоящей статьи
G. A. Melnichenko
Endocrinology Research Centre of the Ministry of Health of Russian Federation
Russian Federation
Competing Interests:
Russian Federation
Galina A. Melnichenko, MD, PhD, Professor
Moscow
Competing Interests:
Авторы декларируют отсутствие явных и потенциальных конфликтов интересов, связанных с содержанием настоящей статьи
O. R. Grigoryan
Endocrinology Research Centre of the Ministry of Health of Russian Federation
Russian Federation
Competing Interests:
Russian Federation
Olga R. Grigoryan, MD, Doctor of Sciences, professor
Moscow
Competing Interests:
Авторы декларируют отсутствие явных и потенциальных конфликтов интересов, связанных с содержанием настоящей статьи
R. V. Rozhivanov
Endocrinology Research Centre of the Ministry of Health of Russian Federation
Russian Federation
Competing Interests:
Russian Federation
Roman V. Rozhivanov, MD, PhD
Moscow
Competing Interests:
Авторы декларируют отсутствие явных и потенциальных конфликтов интересов, связанных с содержанием настоящей статьи
R. K. Mikheev
Endocrinology Research Centre of the Ministry of Health of Russian Federation
Russian Federation
Competing Interests:
Russian Federation
Robert K. Mikheev, MD, postgraduate student
11 Dm. Ulyanova street, 117036 Moscow
Competing Interests:
Авторы декларируют отсутствие явных и потенциальных конфликтов интересов, связанных с содержанием настоящей статьи
M. O. Chernova
Endocrinology Research Centre of the Ministry of Health of Russian Federation
Russian Federation
Competing Interests:
Russian Federation
Mariia O. Chernova, MD, PhD-student
Moscow
Competing Interests:
Авторы декларируют отсутствие явных и потенциальных конфликтов интересов, связанных с содержанием настоящей статьи
E. R. Rozhivanova
Endocrinology Research Centre of the Ministry of Health of Russian Federation
Russian Federation
Competing Interests:
Russian Federation
Ekaterina R. Rozhivanovа, MD-student
Moscow
Competing Interests:
Авторы декларируют отсутствие явных и потенциальных конфликтов интересов, связанных с содержанием настоящей статьи
References
1. Radzinsky V.E., Khamoshina M.B., Raevskaya O.A. et al. Essays about endocrine gynecology (edited by V..Radzinsky), Moscow Status Praesens, 2023 – p.534)
2. Karakhalis LY. Correction of menopausal disorders: new possibilities of menopausal hormone therapy. Meditsinskiy sovet = Medical Council. 2022;(5):112-116. (In Russ.) doi: https://doi.org/10.21518/2079-701X-2022-16-5-112-116
3. Grigoryan OR, Frolova TM, Mikheev RK, et al. The dual role of the menopausal hormonal therapy as the enhancer of pleiotropic telomere rejuvenation and the silencer of cellular aging (literature review). Problems of Endocrinology. 2022;68(3):105-112. doi: https://doi.org/10.14341/probl12895
4. Dedov I., Shestakova M., Mayorov A., et al. Standards of Specialized Diabetes Care / Edited by Dedov I.I., Shestakova M.V., Mayorov A.Yu. 11th Edition. Diabetes mellitus. 2023;26(2S):1-157. (In Russ.) doi: https://doi.org/10.14341/DM13042
5. Oppenheimer JH, Braverman LE, Toft A, Jackson IM, Ladenson PW. A therapeutic controversy. Thyroid hormone treatment: when and what? J Clin Endocrinol Metab. 1995;80(10):2873-2883. doi: https://doi.org/10.1210/jcem.80.10.7559868
6. Dedov I.I., Mokrysheva N.G., Melnichenko G.A., Rozhivanov R.V., Kamalov A.A., Mkrtumyan А.M., Khalimov Yu.Sh., Vorokhobina N.V. Draft of Russian Clinical Practice Guidelines «Male hypogonadism». Obesity and metabolism. 2021;18(4):496-507. (In Russ.) doi: https://doi.org/10.14341/omet12817
7. Clinical recommendations of the Russian Ministry of Health “Menopause and climacteric conditions about females” https://cr.minzdrav.gov.ru/schema/117_2?ysclid=lvog02w9o4540486463
8. Rivera R, Yacobson I, Grimes D. The mechanism of action of hormonal contraceptives and intrauterine contraceptive devices. Am J Obstet Gynecol. 1999;181(5 Pt 1):1263-1269. doi: https://doi.org/10.1016/s0002-9378(99)70120-1
9. Ashfaq S, Can AS. Danazol. In: StatPearls. Treasure Island (FL): StatPearls Publishing. 2023;11
10. Herkert D, Meljen V, Muasher L, et al. Human Chorionic Gonadotropin-A Review of the Literature. Obstet Gynecol Surv. 2022;77(9):539-546. doi: https://doi.org/10.1097/OGX.0000000000001053
11. Boeri L, Capogrosso P, Salonia A. Gonadotropin Treatment for the Male Hypogonadotropic Hypogonadism. Curr Pharm Des. 2021;27(24):2775-2783. doi: https://doi.org/10.2174/1381612826666200523175806
12. Gibreel A, Bhattacharya S. Recombinant follitropin alfa/lutropin alfa in fertility treatment. Biologics. 2010;4:5-17
13. Dedov I.I., Melnichenko G.A., Rozhivanov R.V., Kurbatov D.G. Guidelines for the Diagnosis and Treatment of testosterone deficiency (hypogonadism) in male patients. Problems of Endocrinology. 2016;62(6):78-80. doi: https://doi.org/10.14341/probl201662678-80
14. Dohle GR, Arver S, Bettocchi C, Jones TH, Kliesch S. Male hypogonadism [Internet]. Arnhem: European Association of Urology; c2020 [cited 2020 Aug 4]. Available from: https://uroweb.org/guideline/male-hypogonadism
15. Al-Sharefi A, Quinton R. Current National and International Guidelines for the Management of Male Hypogonadism: Helping Clinicians to Navigate Variation in Diagnostic Criteria and Treatment Recommendations. Endocrinol Metab. 2020;35(3):526-540. doi: https://doi.org/10.3803/EnM.2020.760
16. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men with Hypogonadism: An Endocrine Society. J Clin Endocrinol Metab. 2018;103:1715-44. doi: https://doi.org/10.1210/jc.2018-00229
17. Yeap BB, Grossmann M, McLachlan RI, et al. Endocrine society of Australia position statement on male hypogonadism (Part 1): Assessment and indications for testosterone therapy. Med J Aust. 2016;205:173-8. doi: https://doi.org/10.5694/MJA16.00393
18. Dean JD, McMahon CG, Guay AT, et al. The International Society for Sexual Medicine’s Process of Care for the Assessment and Management of Testosterone Deficiency in Adult Men. J Sex Med. 2015;12(8):1660-1686. doi: https://doi.org/10.1111/jsm.12952
19. Hackett G, Kirby M, Edwards D, et al. British Society for Sexual Medicine Guidelines on Adult Testosterone Deficiency, with Statements for UK Practice. J Sex Med. 2017;14(12):1504-1523. doi: https://doi.org/10.1016/j.jsxm.2017.10.067
20. Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol. 2018;200(2):423-432. doi: https://doi.org/10.1016/j.juro.2018.03.115
21. Wu FCW, Tajar A, Beynon JM, et al. Identification of Late-Onset Hypogonadism in Middle-Aged and Elderly Men. N Engl J Med. 2010;363(2):123-135. doi: https://doi.org/10.1056/NEJMoa0911101
22. Tajar A, Huhtaniemi IT, O’Neill TW, et al. Characteristics of Androgen Deficiency in Late-Onset Hypogonadism: Results from the European Male Aging Study (EMAS). J Clin Endocrinol Metab. 2012;97(5):1508-1516. doi: https://doi.org/10.1210/jc.2011-2513
23. Grossmann M, Matsumoto AM. A Perspective on Middle-Aged and Older Men With Functional Hypogonadism: Focus on Holistic Management. J Clin Endocrinol Metab. 2017;102(3):1067-1075. doi: https://doi.org/10.1210/jc.2016-3580
24. Mazzola CR, Katz DJ, Loghmanieh N, Nelson CJ, Mulhall JP. Predicting Biochemical Response to Clomiphene Citrate in Men with Hypogonadism. J Sex Med. 2014. doi: https://doi.org/10.1111/jsm.12592
Supplementary files
Review
For citations:
Andreeva E.N., Melnichenko G.A., Grigoryan O.R., Rozhivanov R.V., Mikheev R.K., Chernova M.O., Rozhivanova E.R. The most prominent terminological problems in reproductive medicine. Bulletin of Reproductive Health. 2024;3(2):44-48. (In Russ.) https://doi.org/10.14341/brh12737
Views:
235
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
